Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,241,987 papers from all fields of science
Search
Sign In
Create Free Account
Recurrent Chronic Lymphoid Leukemia
Known as:
CLL, relapsed
, Recurrent Chronic Lymphocytic Leukemia
, chronic lymphocytic leukemia, relapsed
Expand
The reemergence of chronic lymphocytic leukemia after a period of remission.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
27 relations
Atypical lymphocyte
B lymphoblast
B-Lymphocytes
BCL3 gene
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia
C. Vitale
,
A. Ferrajoli
Expert Review of Hematology
2020
Corpus ID: 220717712
ABSTRACT Introduction In patients with recurrent chronic lymphocytic leukemia (CLL), treatment with targeted agents such as…
Expand
2016
2016
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion
F. Cavazzini
,
E. Lista
,
+6 authors
A. Cuneo
Leukemia and Lymphoma
2016
Corpus ID: 3881724
Autoimmune hemolytic anemia (AIHA) is one of the most common disease-specific complications of chronic lymphocytic leukemia (CLL…
Expand
2016
2016
Idelalisib-induced pneumonitis
Arjun Gupta
,
H. Li
BMJ Case Reports
2016
Corpus ID: 34111957
A woman in her 40s with relapsed follicular lymphoma presented with a few days history of shortness of breath and cough producing…
Expand
2014
2014
Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia
Ekaterina Kim
,
L. Werner
,
+9 authors
J. Burger
2014
Corpus ID: 208389474
Introduction: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) has proved to be an effective targeted therapy in…
Expand
2013
2013
Long‐term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia
F. Spina
,
Francesca Rezzonico
,
L. Farina
,
P. Corradini
European Journal of Haematology
2013
Corpus ID: 23137348
Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). We report the first case of long‐term molecular…
Expand
2011
2011
Time to put the CAR-T before the horse.
C. Jacobson
,
J. Ritz
Blood
2011
Corpus ID: 206905213
In this issue of Blood , Brentjens and colleagues report on the feasibility, tolerability, and persistence of autologous CD19…
Expand
Review
2010
Review
2010
Secondary cervical cancer in a patient with chronic lymphocytic leukemia and recurrent chronic lymphocytic leukemia mimicking recurrent cervical dysplasia: a case report.
Joseph Magley
,
C. Moyers
,
Karen S. Ballard
,
S. Tedjarati
Journal of reproductive medicine
2010
Corpus ID: 27866306
BACKGROUND Patients with chronic lymphocytic leukemia (CLL) have up to a 3-fold risk of site-specific secondary cancers. The only…
Expand
Review
2010
Review
2010
Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study.
A. Kater
,
S. Tonino
Clinical Lymphoma, Myeloma & Leukemia
2010
Corpus ID: 45521631
In recent years, considerable advances have been made in first-line treatment strategies for chronic lymphocytic leukemia (CLL…
Expand
2002
2002
Handling and disposal of monoclonal antibodies.
J. Estes
Clinical Journal of Oncology Nursing
2002
Corpus ID: 42731675
A NSWER: Monoclonal antibodies (MoAbs) are forms of biotherapy that are being used increasingly for diagnosis and targeted…
Expand
2001
2001
Combination Fludarabine, Cyclophosphamide, and Rituximab for Previously Treated Patients With Chronic Lymphocytic Leukemia
S. O'brien
2001
Corpus ID: 182648301
Treatment options for patients with relapsed chronic lymphocytic leukemia (CLL) are limited. In this report, we present our…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required